Successful Treatment and Secondary Prevention of Venous Thrombosis Secondary to Behçet Disease with Rivaroxaban

Abstract EN

We here present the successful initial treatment and secondary prophylaxis of superficial venous thrombosis secondary to Behçet’s disease by a novel anticoagulant drug, rivaroxaban (Xarelto®).

To our knowledge, this is the first case of using an oral direct inhibitor of FXa in this setting.

Our findings are promising; the outcome was favourable without any adverse effect noted.

We propose that the patients with Behçet’s disease and venous thrombosis might benefit from the advantages of the new anticoagulant drug.